Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
Paolo Angelo CortesiGionata FiorinoLaurent Peyrin BirouletLorenzo Giovanni MantovaniVipul JairathKristine ParidaensFredrik L AnderssonSilvio DanesePublished in: Alimentary pharmacology & therapeutics (2022)
T2T-FC approach resulted in a higher benefit for mild-moderate UC patients in terms of time in remission and incidence of relapse but was associated with higher costs. Clinical trials and real-world clinical studies are needed to provide additional data on the cost-benefit of this approach.
Keyphrases
- ulcerative colitis
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- high intensity
- risk factors
- peritoneal dialysis
- prognostic factors
- rheumatoid arthritis
- disease activity
- big data
- machine learning
- systemic lupus erythematosus
- artificial intelligence
- data analysis
- double blind
- study protocol